{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:00:39Z","timestamp":1764403239995,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Hepatic diseases pose a significant public health concern. Regardless of the severity of hepatic fibrosis, treatment is recommended for all chronic hepatitis C virus (HCV) subjects. However, fibrosis and steatosis assessment remains crucial for evaluating the prognosis, progression, and hepatic disease monitoring, particularly following the treatment with direct-acting antivirals (DAAs). The aim of our study was to evaluate the impact of metabolic factors and the extent of hepatic fibrosis and fat accumulation in chronic HCV infection subjects. Additionally, another objective was to investigate modifications regarding fibrosis and steatosis three months after a successful sustained viral response (SVR). A total of 100 patients with compensated cirrhosis and chronic hepatitis C (CHC) were included in our study. These patients received treatment with DAA and underwent Fibromax assessment before and three months post SVR. After DAA treatment, a significant decrease was observed in the degree of hepatic fibrosis and hepatic steatosis. This regression was evident three months following the achievement of SVR. Chronic viral hepatitis C may trigger risk factors for metabolic syndromes, such as obesity and type 2 diabetes mellitus. Conclusions: It is crucial to monitor metabolic factors and take timely measures to prevent or treat metabolic syndrome in patients with chronic viral hepatitis C.<\/jats:p>","DOI":"10.3390\/metabo13040571","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T02:30:03Z","timestamp":1681785003000},"page":"571","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Influence of Metabolic Factors in Patients with Chronic Viral Hepatitis C Who Received Oral Antiviral Treatment"],"prefix":"10.3390","volume":"13","author":[{"given":"Oana Irina","family":"Gavril","sequence":"first","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu Sebastian","family":"Gavril","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-9327","authenticated-orcid":false,"given":"Florin","family":"Mitu","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Academy of Medical Sciences of Romania, Bucuresti 030171, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otilia","family":"Gavrilescu","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-8839","authenticated-orcid":false,"given":"Iolanda Valentina","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Tatarciuc","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Drugescu","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei Catalin","family":"Oprescu","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (II), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Gherasim","sequence":"additional","affiliation":[{"name":"Morpho-Functional Department, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mihalache","sequence":"additional","affiliation":[{"name":"Morpho-Functional Department, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina Mihaela","family":"Esanu","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.12998\/wjcc.v6.i13.589","article-title":"Update on global epidemiology of viral hepatitis and preventive strategies","volume":"6","author":"Meryem","year":"2018","journal-title":"World J. Clin. Cases"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17081","DOI":"10.1038\/s41598-019-53051-2","article-title":"Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma","volume":"19","author":"Kamp","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/cld.1082","article-title":"Direct-Acting Antiviral Therapy and Hepatocellular Carcinoma","volume":"17","author":"Rich","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_4","first-page":"123","article-title":"Liver transplantation around the world","volume":"22","author":"Trotter","year":"2017","journal-title":"Liver Transpl."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gavril, O.I., Arhire, L.I., Gavril, R.S., Zota, M.I., Gherasim, A., Nita, O., Drugescu, A., Oprescu, A.C., Esanu, I.M., and Mitu, F. (2021). Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients. Medicina, 15.","DOI":"10.3390\/medicina57111249"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of Hepatocellular Carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.dld.2008.05.009","article-title":"Alcohol and viral hepatitis A mini-review","volume":"41","author":"Gitto","year":"2009","journal-title":"Dig. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Bochud","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.14218\/JCTH.2015.00051","article-title":"Hepatitis C Virus, Insulin Resistance, and Steatosis","volume":"4","author":"Kralj","year":"2016","journal-title":"J. Clin. Translational Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1074\/jbc.M109.045740","article-title":"Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH\/NAD+","volume":"285","author":"Seronello","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity","volume":"33","author":"Adinolfi","year":"2001","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0168-8278(05)80631-2","article-title":"Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population","volume":"21","author":"Allison","year":"1994","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4329\/wjr.v3.i7.188","article-title":"Is ARFI elastography reliable for predicting fibrosisseverity in chronic HCV hepatitis?","volume":"3","author":"Sporea","year":"2011","journal-title":"World J. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/apt.14990","article-title":"Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease","volume":"48","author":"Munteanu","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/jim-2018-000864","article-title":"Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus","volume":"67","author":"Bril","year":"2018","journal-title":"J. Investig. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/MEG.0000000000001064","article-title":"Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference","volume":"30","author":"Poynard","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of Hepatitis C Virus Infection in Patients with Cirrhosis Reduces Risk of Liver and Non-Liver Complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2893.2005.00669.x","article-title":"Hepatitis C and steatosis: A reappraisal","volume":"13","author":"Lonardo","year":"2006","journal-title":"J. Viral Hepatitis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/hep4.1228","article-title":"Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C","volume":"21","author":"Pan","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s10620-019-05886-y","article-title":"Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy","volume":"65","author":"Huang","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jvh.13204","article-title":"Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C","volume":"27","author":"Laursen","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.23736\/S1120-4826.20.02619-1","article-title":"Molecular mechanisms of hepatic fibrosis in chronic liver diseases","volume":"32","author":"Rosso","year":"2020","journal-title":"Minerva Biotecnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Emerging Risk Factors Collaboration\/EPIC-CVD\/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: Combined analysis of individual-participant data for 599,912 current drinkers in 83 prospective studies","volume":"391","author":"Wood","year":"2018","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drugalcdep.2016.10.021","article-title":"Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents","volume":"1","author":"Tsui","year":"2016","journal-title":"Drug. Alcohol. Depend."},{"key":"ref_27","first-page":"233","article-title":"History of alcohol use does not predict HCV direct acting antiviral treatment outcomes","volume":"27","author":"IaOkwor","year":"2022","journal-title":"J. Assoc. Med. Microbiol. Infect. Dis. Can."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27491","DOI":"10.1136\/bmjopen-2018-027491","article-title":"Estimation of fibrosis progression rates for chronic hepatitis C: A systematic review and meta-analysis update","volume":"9","author":"Erman","year":"2019","journal-title":"BMJ Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jhep.2003.11.004","article-title":"The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C. patients","volume":"40","author":"Patton","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/gut.2003.018770","article-title":"Steatosis a ffects chronic hepatitis C progression in a genotype speci fic way","volume":"53","author":"Fabris","year":"2004","journal-title":"Gut"},{"key":"ref_31","first-page":"794","article-title":"Anthropometric parameters\u2014Predictive factors for cardio-metabolic diseases","volume":"116","author":"Mihalache","year":"2012","journal-title":"Rev. Med. Chir. Soc. Med. Nat. Lasi"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/j.1572-0241.2002.05995.x","article-title":"Contribution of obesity to hepatitis C-related fibrosis progression","volume":"97","author":"Ortiz","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1007\/s11606-020-06004-9","article-title":"Hepatitis C Virus Cure and Obesity: Watch the Weight","volume":"35","author":"Mukhtar","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/13596535221115253","article-title":"Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C","volume":"27","author":"Nkwocha","year":"2022","journal-title":"Antivir. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8814135","DOI":"10.1155\/2020\/8814135","article-title":"The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients","volume":"2020","author":"Sirinawasatien","year":"2020","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_36","first-page":"425","article-title":"The central role of the non alcoholic fatty liver disease in metabolic syndrome","volume":"116","author":"Hurjui","year":"2012","journal-title":"Rev. Med. Chir. Soc. Med. Nat. Lasi"},{"key":"ref_37","first-page":"692","article-title":"Non-alcoholic fatty liver disease is associated with cardiovascular risk factors of metabolic syndrome","volume":"116","author":"Hurjui","year":"2012","journal-title":"Rev. Med. Chir. Soc. Med. Nat. Lasi"},{"key":"ref_38","first-page":"39","article-title":"Changes in hepatic fibrosis stages after achieving SVR following direct-acting anti-viral treatment: A prospective stud","volume":"18","author":"Shina","year":"2020","journal-title":"GastroHep"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdi.13756","article-title":"Non-alcoholic fatty liver disease and type\u20092 diabetes: An update","volume":"13","author":"Lee","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3803\/EnM.2019.34.3.226","article-title":"Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective","volume":"34","author":"Rhee","year":"2019","journal-title":"Endocrinol. Metab."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/4\/571\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:17:37Z","timestamp":1760123857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/4\/571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["metabo13040571"],"URL":"https:\/\/doi.org\/10.3390\/metabo13040571","relation":{},"ISSN":["2218-1989"],"issn-type":[{"type":"electronic","value":"2218-1989"}],"subject":[],"published":{"date-parts":[[2023,4,17]]}}}